RxDoctor Payments Data

Cary Bybee, MD

Family Medicine · Shelby, MTNPI 1265852586

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.3% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,265 and has fallen 97.3% since, to $35 in 2025. Among family medicine clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,026in general payments, 2019–2025

Across 108 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$407
  • AstraZeneca$347
  • Pfizer$218
  • Takeda Pharmaceuticals U.S.A., Inc.$113
  • Astellas Pharma US Inc$109
  • Boehringer Ingelheim$96
  • plus $735 from 18 others

What the payments were for

  • Food & beverage$1,95196%
  • Education$754%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,026 in reported general payments places this provider in the 95th percentile of 426 family medicine providers in Montana.

See all family medicine providers in Montana

Medicare billing

Part B allowed, 2024
$1,242
Medicare patients
68
Services billed
109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban43$31,378
JardianceEmpagliflozin14$13,587
Albuterol Sulfate HfaAlbuterol Sulfate13$374
Atorvastatin Calcium39$258
Levothyroxine Sodium39$250
Omeprazole23$246
Gabapentin23$239
Lisinopril36$201
Fluticasone Propionate13$166
Losartan Potassium19$159
Tamsulosin Hcl19$138
Cephalexin30$133
Pantoprazole Sodium26$114
Hydrochlorothiazide19$108
Amlodipine Besylate19$102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$218$31,37843 claims
Boehringer IngelheimJardiance$96$13,58714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 426 family medicine providers in Montana.

Other family medicine in Shelby

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →